- Trials with a EudraCT protocol (28)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
28 result(s) found for: Monoclonal B Cell Lymphocytosis.
Displaying page 1 of 2.
EudraCT Number: 2008-004932-19 | Sponsor Protocol Number: OMB110911 | Start Date*: 2009-01-27 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia | ||||||||||||||||||||||||||||||||||||||
Medical condition: Chronic Lymphocytic Leukaemia | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) SE (Completed) BE (Prematurely Ended) CZ (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) GB (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-007587-21 | Sponsor Protocol Number: CLL10 | Start Date*: 2008-09-05 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocyti... | |||||||||||||
Medical condition: patients (age 18 years or older) with chronic lymphocytic leukemia: Stage Binet C or stage Binet B and A requiring treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) DK (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000243-10 | Sponsor Protocol Number: Hx-CD20-407 | Start Date*: 2007-05-16 | |||||||||||
Sponsor Name:Glaxo SmithKline Research and Development Limited | |||||||||||||
Full Title: An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with fludarabine and cyclophosphamide, in patients with previ... | |||||||||||||
Medical condition: B-cell Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LT (Completed) CZ (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004454-17 | Sponsor Protocol Number: ACE-CL-309 | Start Date*: 2016-10-24 | |||||||||||
Sponsor Name:Acerta Pharma BV | |||||||||||||
Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator’s Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects with Rela... | |||||||||||||
Medical condition: Relapsed or Refractory Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Ongoing) SK (Completed) SE (Completed) ES (Ongoing) CZ (Ongoing) AT (Completed) DE (Completed) FR (Completed) BG (Completed) PL (Ongoing) HR (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000569-35 | Sponsor Protocol Number: CLL2-BIG | Start Date*: 2014-12-29 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA1... | |||||||||||||
Medical condition: Fit and unfit patients with previously untreated or relapsed/refractory CLL requiring treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-004476-19 | Sponsor Protocol Number: PCYC-1117-CA | Start Date*: 2013-01-25 | ||||||||||||||||
Sponsor Name:Pharmacyclics LLC | ||||||||||||||||||
Full Title: An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Ly... | ||||||||||||||||||
Medical condition: An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Ly... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) SE (Completed) BE (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005530-64 | Sponsor Protocol Number: ACE-CL-006 | Start Date*: 2015-07-31 | |||||||||||
Sponsor Name:Acerta Pharma BV | |||||||||||||
Full Title: A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia | |||||||||||||
Medical condition: High Risk Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) NL (Ongoing) BE (Ongoing) FR (Completed) ES (Ongoing) DK (Completed) DE (Completed) PL (Ongoing) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003206-41 | Sponsor Protocol Number: LOXO-BTK-20030(J2N-OX-JZNU) | Start Date*: 2022-08-03 | |||||||||||
Sponsor Name:Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) versus Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314) | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) HU (Ongoing) ES (Ongoing) IT (Ongoing) CZ (Trial now transitioned) AT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001573-89 | Sponsor Protocol Number: D8220C00008 | Start Date*: 2019-09-24 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia | |||||||||||||
Medical condition: Chronic lymphocytic leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) GB (GB - no longer in EU/EEA) FI (Ongoing) ES (Ongoing) FR (Ongoing) DK (Ongoing) NL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005582-73 | Sponsor Protocol Number: ACE-CL-007 | Start Date*: 2015-07-03 | |||||||||||
Sponsor Name:Acerta Pharma BV | |||||||||||||
Full Title: A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previ... | |||||||||||||
Medical condition: Untreated Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) LT (Ongoing) HU (Ongoing) ES (Ongoing) BE (Ongoing) SE (Ongoing) DE (Ongoing) PL (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005758-36 | Sponsor Protocol Number: UTX-TGR-304 | Start Date*: 2016-10-28 | |||||||||||
Sponsor Name:TG Therapeutics | |||||||||||||
Full Title: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 (Umbralisib) Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chr... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000694-23 | Sponsor Protocol Number: PCYC-1112-CA | Start Date*: 2012-08-08 | |||||||||||
Sponsor Name:Pharmacyclics LLC an Abbvie Company | |||||||||||||
Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia... | |||||||||||||
Medical condition: relapsed or refractory CLL/SLL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) PL (Completed) ES (Completed) IT (Completed) AT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004606-41 | Sponsor Protocol Number: CLL2-GIVe | Start Date*: 2016-08-11 | |||||||||||
Sponsor Name:University Hospital Ulm | |||||||||||||
Full Title: A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II TRIAL OF IBRUTINIB PLUS VENETOCLAX PLUS OBINUTUZUMAB IN PHYSICALLY FIT (CIRS ≤ 6 & NORMAL CREATININE CLEARANCE) OR UNFIT (CIRS >6 OR CREATININE CLEAR... | |||||||||||||
Medical condition: Physically fit and unfit patients with TP53 deletion (17p-) and/or mutation and previously untreated CLL requiring therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003967-23 | Sponsor Protocol Number: PCYC-1115-CA | Start Date*: 2013-02-05 | |||||||||||
Sponsor Name:Pharmacyclics, Incorporated | |||||||||||||
Full Title: A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton’s Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older with Treatment-naive Chronic Lymphocytic L... | |||||||||||||
Medical condition: Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IE (Completed) CZ (Completed) DE (Completed) ES (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003737-15 | Sponsor Protocol Number: ACE-CL-110 | Start Date*: 2017-10-16 | |||||||||||
Sponsor Name:Acerta Pharma BV | |||||||||||||
Full Title: A Phase 1/2 Proof-of-Concept Study Investigating AZD6738 monotherapy and Acalabrutinib in Combination with AZD6738 (ATR inhibitor) in Subjects with Relapsed or Refractory High-risk Chronic Lymphocy... | |||||||||||||
Medical condition: Relapsed or Refractory High-risk Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019554-41 | Sponsor Protocol Number: 16201 | Start Date*: 2010-10-19 | |||||||||||
Sponsor Name:Trubion Pharmaceuticals | |||||||||||||
Full Title: A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Bendamustine vs. Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia / Estudio... | |||||||||||||
Medical condition: leucemia linfocítica crónica | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000043-49 | Sponsor Protocol Number: LOXO-BTK-20022 | Start Date*: 2021-09-22 | |||||||||||
Sponsor Name:Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Sm... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) ES (Ongoing) CZ (Ongoing) PL (Ongoing) NO (Ongoing) HU (Ongoing) DK (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004554-30 | Sponsor Protocol Number: LOXO-BTK-20020 | Start Date*: 2021-06-04 | |||||||||||
Sponsor Name:Loxo Oncology Inc | |||||||||||||
Full Title: A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Ongoing) AT (Ongoing) CZ (Ongoing) DE (Ongoing) HU (Ongoing) BE (Ongoing) IT (Ongoing) ES (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022260-12 | Sponsor Protocol Number: 1947 | Start Date*: 2011-03-24 | |||||||||||
Sponsor Name:King's College Hospital NHS Foundation Trust | |||||||||||||
Full Title: A Phase II trial of broad spectrum antibiotic therapy for early stage chronic lymphocytic leukaemia. | |||||||||||||
Medical condition: Chronic Lymphocytic Leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000580-40 | Sponsor Protocol Number: CLL2-BAG | Start Date*: 2015-04-23 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax) followed ... | |||||||||||||
Medical condition: Fit and unfit patients with previously untreated or relapsed/refractory CLL requiring treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.